Epa but not dha appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: Evidence from a meta-analysis of randomized controlled trials

Journal of the American College of Nutrition

Volumn 28, Issue 5, 2009, Pages 525-542

  Martins, Julian G ^a  

^a Academy of Nutritional Medicine   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID;

DEPRESSION; DIET SUPPLEMENTATION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

DEPRESSIVE DISORDER; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77954947300     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2009.10719785     Document Type: Article

References (97)

1. Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, Dragomirecka E, Kohn R, Keller M, Kessler RC, Kawakami N, Kilic C, Offord D, Ustun TB, Wittchen HU: The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 12:3-21, 2003.
2. Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT, van Tilburg W: Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 58:221-227, 2001.
3. Sobocki P, Jönsson B, Angst J, Rehnberg C: Cost of depression in Europe. J Ment Health Policy Econ 9:87-98, 2006.
4. Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:442, 2006.
5. Klerman GL, Weissman MM: Increasing rates of depression. JAMA 261:2229-2235, 1989.
6. Jemal A, Ward E, Anderson RN, Murray T, Thun MJ: Widening of socioeconomic inequalities in U.S. death rates, 1993-2001. PLoS One 3: 2181, 2008.
7. O'Flaherty M, Ford E, Allender S, Scarborough P, Capewell S: Coronary heart disease trends in England and Wales from 1984 to 2004: concealed levelling of mortality rates among young adults. Heart 94:178-181, 2008.
8. Puri BK: Cardiovascular disease and depression: the PUFA connection. Int J Clin Pract 62:355-357, 2008.
9. Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27:24-31, 2006.
10. Pace TW, Hu F, Miller AH: Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 21:9-19, 2007.
11. Calder PC: n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83:1505S-1519S, 2006.
12. Kiecolt-Glaser JK, Belury MA, Porter K, Beversdorf DQ, Lemeshow S, Glaser R: Depressive symptoms, omega-6:omega-3 fatty acids, and inflammation in older adults. Psychosom Med 69:217-224, 2007.
13. Appleton KM, Peters TJ, Hayward RC, Heatherley SV, McNaughton SA, Rogers PJ, Gunnell D, Ness AR, Kessler D: Depressed mood and n-3 polyunsaturated fatty acid intake from fish: non-linear or confounded association? Soc Psychiatry Psychiatr Epidemiol 42:100-104, 2007.
14. Appleton KM, Woodside JV, Yarnell JW, Arveiler D, Haas B, Amouyel P, Montaye M, Ferrieres J, Ruidavets JB, Ducimetiere P, Bingham A, Evans A: Depressed mood and dietary fish intake: direct relationship or indirect relationship as a result of diet and lifestyle? J Affect Disord 104:217-223, 2007.
15. Hibbeln JR: Fish consumption and major depression. Lancet 351:1213, 1998.
16. Hibbeln JR: Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a crossnational, ecological analysis. J Affect Disord 69:15-29, 2002.
17. Noaghiul S, Hibbeln JR: Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry 160:2222-2227, 2003.
18. Silvers KM, Scott KM: Fish consumption and self-reported physical and mental health status. Public Health Nutr 5:427-431, 2002.
19. Tanskanen A, Hibbeln JR, Tuomilehto J, Uutela A, Haukkala A, Viinamaki H, Lehtonen J, Vartiainen E: Fish consumption and depressive symptoms in the general population in Finland. Psychiatr Serv 52:529-531, 2001.
20. Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Räsänen P: Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord 82:447-452, 2004.
21. Adams PB, Lawson S, Sanigorski A, Sinclair AJ: Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 31 Suppl:S157-S161, 1996.
22. Conklin SM, Harris JI, Manuck SB, Yao JK, Hibbeln JR, Muldoon MF: Serum omega-3 fatty acids are associated with variation in mood, personality and behavior in hypercholesterolemic community volunteers. Psychiatry Res 152:1-10, 2007.
23. Edwards R, Peet M, Shay J, Horrobin D: Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 48:149-155, 1998.
24. Féart C, Peuchant E, Letenneur L, Samieri C, Montagnier D, Fourrier-Reglat A, Barberger-Gateau P: Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: data from the Bordeaux sample of the Three-City Study. Am J Clin Nutr 87:1156-1162, 2008.
25. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY: Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 85:275-291, 1999.
26. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H: Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 38:35-46, 1996.
27. Peet M, Murphy B, Shay J, Horrobin D: Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 43:315-319, 1998.
28. De Vriese SR, Christophe AB, Maes M: In humans, the seasonal variation in poly-unsaturated fatty acids is related to the seasonal variation in violent suicide and serotonergic markers of violent suicide. Prostaglandins Leukot Essent Fatty Acids 71:13-18, 2004.
29. Huan M, Hamazaki K, Sun Y, Itomura M, Liu H, Kang W, Watanabe S, Terasawa K, Hamazaki T: Suicide attempt and n-3 fatty acid levels in red blood cells: a case control study in China. Biol Psychiatry 56:490-496, 2004.
30. Sublette ME, Hibbeln JR, Galfalvy H, Oquendo MA, Mann JJ: Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. Am J Psychiatry 163:1100-1102, 2006.
31. Rose G: Sick individuals and sick populations. Int J Epidemiol 14:32-38, 1985.
32. Berton O, Nestler EJ: New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7:137-151, 2006.
33. Puri BK, Counsell SJ, Hamilton G, Richardson AJ, Horrobin DF: Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover. Int J Clin Pract 55:560-563, 2001.
34. Frangou S, Lewis M, McCrone P: Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebocontrolled study. Br J Psychiatry 188:46-50, 2006.
35. Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayery A, Amini H, Jalali M, Peet M: Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 42:192-198, 2008.
36. Nemets B, Stahl Z, Belmaker RH: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 159:477-479, 2002.
37. Peet M, Horrobin DF: A dose-ranging study of the effects of ethyleicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 59:913-919, 2002.
38. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56:407-412, 1999.
39. Su KP, Huang SY, Chiu CC, Shen WW: Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebocontrolled trial. Eur Neuropsychopharmacol 13:267-271, 2003.
40. Su KP, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC, Pariante CM: Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69:644-651, 2008.
41. Hallahan B, Hibbeln JR, Davis JM, Garland MR: Omega-3 fatty acid supplementation in patients with recurrent self-harm. Singlecentre double-blind randomised controlled trial. Br J Psychiatry 190:118-122, 2007.
42. da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, Ferraz AC: Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 111:351-359, 2008.
43. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH: Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 163:1098-1100, 2006.
44. Behan PO, Behan WM, Horrobin D: Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand 82:209-216, 1990.
45. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M: A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158:2071-2074, 2001.
46. Frangou S, Lewis M, Wollard J, Simmons A: Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J Psychopharmacol 21:435-439, 2007.
47. Grenyer BF, Crowe T, Meyer B, Owen AJ, Grigonis-Deane EM, Caputi P, Howe PR: Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 31:1393-1396, 2007.
48. Keck PE Jr, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, Altshuler LL, Kupka R, Nolen WA, Leverich GS, Denicoff KD, Grunze H, Duan N, Post RM: Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 60:1020-1022, 2006.
49. Llorente AM, Jensen CL, Voigt RG, Fraley JK, Berretta MC, Heird WC: Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. Am J Obstet Gynecol 188:1348-1353, 2003.
50. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HF, Puryear LJ: A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 160:996-998, 2003.
51. Rees AM, Austin MP, Parker GB: Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial. Aust N Z J Psychiatry 42:199-205, 2008.
52. Rogers PJ, Appleton KM, Kessler D, Peters TJ, Gunnell D, Hayward RC, Heatherley SV, Christian LM, McNaughton SA, Ness AR: No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 99:421-431, 2008.
53. Silvers KM, Woolley CC, Hamilton FC, Watts PM, Watson RA: Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids 72:211-218, 2005.
54. Zanarini MC, Frankenburg FR: omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. AmJ Psychiatry 160:167-169, 2003.
55. Warren G, McKendrick M, Peet M: The role of essential fatty acids in chronic fatigue syndrome. A case-controlled study of redcell membrane essential fatty acids (EFA) and a placebocontrolled treatment study with high dose of EFA. Acta Neurol Scand 99:112-116, 1999.
56. Doornbos B, van Goor SA, Dijck-Brouwer DA, Schaafsma A, Korf J, Muskiet FA: Supplementation of a low dose of DHA or DHA+AA does not prevent peripartum depressive symptoms in a small population based sample. Prog Neuropsychopharmacol Biol Psychiatry 33:49-52, 2009.
57. Freeman MP, Davis M, Sinha P, Wisner KL, Hibbeln JR, Gelenberg AJ: Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord 110:142-148, 2008.
58. Lucas M, Asselin G, Merette C, Poulin MJ, Dodin S: Ethyleicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr 89:641-651, 2009.
59. van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Hoefnagels WH, Beekman AT, de Groot LC: Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 88:706-713, 2008.
60. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE Jr, Marangell LB, Richardson AJ, Lake J, Stoll AL: Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 67:1954-1967, 2006.
61. Lin PY, Su KP: A meta-analytic review of double-blind, placebocontrolled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 68:1056-1061, 2007.
62. Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D, Ness AR: Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 84:1308-1316, 2006.
63. Ross BM, Seguin J, Sieswerda LE: Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis 6:21, 2007.
64. Fux M, Benjamin J, Nemets B: A placebo-controlled cross-over trial of adjunctive EPA in OCD. J Psychiatr Res 38:323-325, 2004.
65. Ness AR, Gallacher JE, Bennett PD, Gunnell DJ, Rogers PJ, Kessler D, Burr ML: Advice to eat fish and mood: a randomised controlled trial in men with angina. Nutr Neurosci 6:63-65, 2003.
66. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-12, 1996.
67. Bax L, Yu LM, Ikeda N, Moons KG: A systematic comparison of software dedicated to meta-analysis of causal studies. BMC Med Res Methodol 7:40, 2007.
68. Fontani G, Corradeschi F, Felici A, Alfatti F, Bugarini R, Fiaschi AI, Cerretani D, Montorfano G, Rizzo AM, Berra B: Blood profiles, body fat and mood state in healthy subjects on different diets supplemented with omega-3 polyunsaturated fatty acids. Eur J Clin Invest 35:499-507, 2005.
69. Hirashima F, Parow AM, Stoll AL, Demopulos CM, Damico KE, Rohan ML, Eskesen JG, Zuo CS, Cohen BM, Renshaw PF: Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry 161:1922-1924, 2004.
70. Rush JA, First MB, Blacker D: ''Handbook of Psychiatric Measures.'' 2nd ed. Washington, DC: American Psychiatric Publishing, Inc., 2008.
71. Singleton N, Bumpstead R, O'Brien M, Lee A, Meltzer H. Psychiatric Morbidity Among Adults Living in Private Households. London: The Stationery Office; 2001. Accessed at: http://www.statistics.gov.uk/downloads/theme_health/psychmorb.pdf
72. Giltay EJ, Gooren LJ, Toorians AW, Katan MB, Zock PL: Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects. Am J Clin Nutr 80:1167-1174, 2004.
73. Burdge GC, Wootton SA: Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br J Nutr 88:411-420, 2002.
74. Blazer DG, Kessler RC, McGonagle KA, Swartz MS: The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 151:979-986, 1994.
75. Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL: Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr 63:1037-1040, 2009.
76. Fujioka S, Hamazaki K, Itomura M, Huan M, Nishizawa H, Sawazaki S, Kitajima I, Hamazaki T: The effects of eicosapentaenoic acid-fortified food on inflammatory markers in healthy subjects-a randomized, placebo-controlled, double-blind study. J Nutr Sci Vitaminol (Tokyo) 52:261-265, 2006.
77. Itomura M, Hamazaki K, Sawazaki S, Kobayashi M, Terasawa K, Watanabe S, Hamazaki T: The effect of fish oil on physical aggression in schoolchildren-a randomized, double-blind, placebo-controlled trial. J Nutr Biochem 16:163-171, 2005.
78. Stevens L, Zhang W, Peck L, Kuczek T, Grevstad N, Mahon A, Zentall SS, Arnold LE, Burgess JR: EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 38:1007-1021, 2003.
79. Posternak MA, Zimmerman M, Keitner GI, Miller IW: A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry 159:191-200, 2002.
80. Lee S, Walker JR, Jakul L, Sexton K: Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety 19:10-19, 2004.
81. Horrobin DF, Jenkins K, Bennett CN, Christie WW: Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukot Essent Fatty Acids 66:83-90, 2002.
82. Arterburn LM, Hall EB, Oken H: Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 83:1467S-1476S, 2006.
83. Carver JD, Benford VJ, Han B, Cantor AB: The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res Bull 56:79-85, 2001.
84. Umegaki K, Hashimoto M, Yamasaki H, Fujii Y, Yoshimura M, Sugisawa A, Shinozuka K: Docosahexaenoic acid supplementation-increased oxidative damage in bone marrow DNA in aged rats and its relation to antioxidant vitamins. Free Radic Res 34:427-435, 2001.
85. Leonardi F, Attorri L, Di Benedetto R, Di Biase A, Sanchez M, Nardini M, Salvati S: Effect of arachidonic, eicosapentaenoic and docosahexaenoic acids on the oxidative status of C6 glioma cells. Free Radic Res 39:865-874, 2005.
86. Yang DY, Pan HC, Yen YJ, Wang CC, Chuang YH, Chen SY, Lin SY, Liao SL, Raung SL, Wu CW, Chou MC, Chiang AN, Chen CJ: Detrimental effects of post-treatment with fatty acids on brain injury in ischemic rats. Neurotoxicology 28:1220-1229, 2007.
87. Fam SS, Murphey LJ, Terry ES, Zackert WE, Chen Y, Gao L, Pandalai S, Milne GL, Roberts LJ, Porter NA, Montine TJ, Morrow JD: Formation of highly reactive A-ring and J-ring isoprostane-like compounds (A4/J4-neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 277:36076-36084, 2002.
88. Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP: Compartmental modeling to quantify alpha-linolenic acid conversion after longer term intake of multiple tracer boluses. J Lipid Res 46:1474-1483, 2005.
89. Rapoport SI, Rao JS, Igarashi M: Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot Essent Fatty Acids 77:251-261, 2007.
90. Lonergan PE, Martin DS, Horrobin DF, Lynch MA: Neuroprotective actions of eicosapentaenoic acid on lipopolysaccharideinduced dysfunction in rat hippocampus. J Neurochem 91:20-29, 2004.
91. Brooks JD, Milne GL, Yin H, Sanchez SC, Porter NA, Morrow JD: Formation of highly reactive cyclopentenone isoprostane compounds (A3/J3-isoprostanes) in vivo from eicosapentaenoic acid. J Biol Chem 283:12043-12055, 2008.
92. Bhattacharya A, Sun D, Rahman M, Fernandes G: Different ratios of eicosapentaenoic and docosahexaenoic omega-3 fatty acids in commercial fish oils differentially alter pro-inflammatory cytokines in peritoneal macrophages from C57BL/6 female mice. J Nutr Biochem 18:23-30, 2007.
93. Zhao Y, Joshi-Barve S, Barve S, Chen LH: Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NFkappaB activation. J Am Coll Nutr 23:71-78, 2004.
94. Sierra S, Lara-Villoslada F, Comalada M, Olivares M, Xaus J: Dietary eicosapentaenoic acid and docosahexaenoic acid equally incorporate as decosahexaenoic acid but differ in inflammatory effects. Nutrition 24:245-254, 2008.
95. Maes M, Mihaylova I, Kubera M, Bosmans E: Why fish oils may not always be adequate treatments for depression or other inflammatory illnesses: docosahexaenoic acid, an omega-3 polyunsaturated fatty acid, induces a Th-1-like immune response. Neuro Endocrinol Lett 28:875-880, 2007.
96. Barrow CJ, Shahidi F: ''Marine Nutraceuticals and Functional Foods.'' Boca Raton, FL: CRC Press, 2007.
97. Nadezhda N, Sushchik MI, Kalachova G: Seasonal dynamics of fatty acid content of a common food fish from the Yenisei river, Siberian grayling, Thymallus arcticus. Food Chem 104:1353-1358, 2007.